BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med 2021;10:536. [PMID: 33540569 DOI: 10.3390/jcm10030536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Kolev M, Barbour T, Baver S, Francois C, Deschatelets P. With complements: C3 inhibition in the clinic. Immunol Rev 2022. [PMID: 36161656 DOI: 10.1111/imr.13138] [Reference Citation Analysis]
2 Müller J, Hamedani NS, Mcrae HL, Rühl H, Oldenburg J, Pötzsch B. Assay for ADAMTS-13 Activity with Flow Cytometric Readout. ACS Omega. [DOI: 10.1021/acsomega.2c02077] [Reference Citation Analysis]
3 Balahura AM, Moroi ȘI, Scafa-Udrişte A, Weiss E, Japie C, Bartoş D, Bădilă E. The Management of Hypertensive Emergencies-Is There a "Magical" Prescription for All? J Clin Med 2022;11:3138. [PMID: 35683521 DOI: 10.3390/jcm11113138] [Reference Citation Analysis]
4 Cui Y, Wei J, Peng X. Case Report: Rabies Vaccine-Induced Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus. Front Immunol 2022;13:851316. [PMID: 35558074 DOI: 10.3389/fimmu.2022.851316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Abou‐ismail MY, Kapoor S, Citla Sridhar D, Nayak L, Ahuja S. Thrombotic microangiopathies: An illustrated review. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12708] [Reference Citation Analysis]
6 Al-Tamimi M, Qiao J, Gardiner EE. The utility of platelet activation biomarkers in thrombotic microangiopathies. Platelets 2022;:1-9. [PMID: 35287530 DOI: 10.1080/09537104.2022.2026912] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fodil S, Zafrani L. Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients. JCM 2022;11:1103. [DOI: 10.3390/jcm11041103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jung JY, Kim JW, Suh CH, Kim HA. Successful treatment of thrombotic thrombocytopenic purpura with plasmapheresis and anti-CD20 antibodies in a patient with immune thrombocytopenia and systemic lupus erythematosus: Case report. Medicine (Baltimore) 2022;101:e28908. [PMID: 35363211 DOI: 10.1097/MD.0000000000028908] [Reference Citation Analysis]
9 Deucher W, Sukumar S, Cataland SR. Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
10 Sun S, Urbanus RT, ten Cate H, de Groot PG, de Laat B, Heemskerk JWM, Roest M. Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. Cells 2021;10:3386. [DOI: 10.3390/cells10123386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
11 Boesen EI, Kakalij RM. Autoimmune-mediated renal disease and hypertension. Clin Sci (Lond) 2021;135:2165-96. [PMID: 34533582 DOI: 10.1042/CS20200955] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Poullin P. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point]. Transfus Clin Biol 2021;28:380-5. [PMID: 34464709 DOI: 10.1016/j.tracli.2021.08.347] [Reference Citation Analysis]
13 Ercig B, Arfman T, Hrdinova J, Wichapong K, Reutelingsperger CPM, Vanhoorelbeke K, Nicolaes GAF, Voorberg J. Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity. J Biol Chem 2021;297:101132. [PMID: 34461090 DOI: 10.1016/j.jbc.2021.101132] [Reference Citation Analysis]
14 Ten Cate H, Lämmle B. Special Issue: "The Latest Clinical Advances in Thrombocytopenia". J Clin Med 2021;10:3463. [PMID: 34441759 DOI: 10.3390/jcm10163463] [Reference Citation Analysis]
15 Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;14:707-19. [PMID: 34275393 DOI: 10.1080/17474086.2021.1956898] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Holmes S, Podger L, Bottomley C, Rzepa E, Bailey KMA, Chandler F. Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom. Hematology 2021;26:465-72. [PMID: 34238132 DOI: 10.1080/16078454.2021.1945236] [Reference Citation Analysis]
17 Alshamam MS, Sumbly V, Khan S, Nso N, Rizzo V. Acquired Thrombotic Thrombocytopenic Purpura in a Newly Diagnosed HIV Patient: A Case Report and Literature Review. Cureus 2021;13:e15967. [PMID: 34336459 DOI: 10.7759/cureus.15967] [Reference Citation Analysis]
18 Wolf ME, Luz B, Niehaus L, Bhogal P, Bäzner H, Henkes H. Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure. J Clin Med 2021;10:1599. [PMID: 33918932 DOI: 10.3390/jcm10081599] [Cited by in Crossref: 24] [Cited by in F6Publishing: 77] [Article Influence: 24.0] [Reference Citation Analysis]
19 Kandah E, Konda R, Kalantary A, Madadha A, Kunadi A. A Novel Case of Cytomegalovirus Pneumonia in an Acquired Thrombotic Thrombocytopenic Purpura Patient Treated With Rituximab. Cureus 2021;13:e14182. [PMID: 33936893 DOI: 10.7759/cureus.14182] [Reference Citation Analysis]